Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization
Author(s) -
Daniel K. Whelligan,
Savade Solanki,
Dawn Taylor,
Douglas W. Thomson,
Kwai-Ming J. Cheung,
Kathy Boxall,
Corine Mas-Droux,
Caterina Barillari,
Samantha Burns,
Charles G. Grummitt,
Ian Collins,
Rob L. M. van Montfort,
G. Wynne Aherne,
Richard Bayliss,
Swen Hoelder
Publication year - 2010
Publication title -
journal of medicinal chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.01
H-Index - 261
eISSN - 1520-4804
pISSN - 0022-2623
DOI - 10.1021/jm1008727
Subject(s) - chemistry , kinase , biochemistry , mitosis , transferase , enzyme , protein kinase a , residue (chemistry) , stereochemistry , computational biology , microbiology and biotechnology , biology
We report herein the first systematic exploration of inhibitors of the mitotic kinase Nek2. Starting from HTS hit aminopyrazine 2, compounds with improved activity were identified using structure-based design. Our structural biology investigations reveal two notable observations. First, 2 and related compounds bind to an unusual, inactive conformation of the kinase which to the best of our knowledge has not been reported for other types of kinase inhibitors. Second, a phenylalanine residue at the center of the ATP pocket strongly affects the ability of the inhibitor to bind to the protein. The implications of these observations are discussed, and the work described here defines key features for potent and selective Nek2 inhibition, which will aid the identification of more advanced inhibitors of Nek2.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom